Friday, June 26, 2015

1930s-like depression: Rajan- WARNS !!!

World economy may slip to 1930s-like depression: Rajan

Reiterates warning against competitive monetary policy easing by central banks

Tuesday, June 23, 2015

SOLAR POWER BUSINESS...!!



SoftBank, Bharti, Foxconn in $20-bn solar power projects JV: 5 key points

SoftBank, Bharti Enterprises and Foxconn Technology teamed up to form a joint venture (JV) to set up a 20 gigawatt (GW) of solar and wind energy projects in India at an investment of about $20 billion.

Japan’s SoftBank, the Sunil Bharti Mittal-led Bharti Enterprises and Taiwan’s Foxconn Technology on Monday teamed up to form a joint venture (JV) to set up a 20 gigawatt (GW) of solar and wind energy projects in India at an investment of about $20 billion. Here are 5 key points:
1. Japan’s SoftBank, the Sunil Bharti Mittal-led Bharti Enterprises and Taiwan’s Foxconn Technology’s joint venture is one of the biggest investment pledges to date in the country’s renewable energy sector.
2. SoftBank is the largest shareholder in Chinese e-commerce firm Alibaba, will have the majority control in the three-way JV company with Bharti and Foxconn as minority stakeholders.
3. SoftBank aims to endorse Prime Minister Narendra Modi’s Make in India and 100 GW of clean energy by 2022 vision.
4. SBG Cleantech will be headed by Manoj Kohli as its executive chairman while Raman Nanda will be the chief executive officer. It will be headquartered in New Delhi.
5. SoftBank had in 2011 set up SB Energy to develop clean energy projects following the Fukushima nuclear disaster.
First Published on June 23, 2015 9:42 am

http://www.financialexpress.com/article/industry/companies/softbank-bharti-foxconn-in-20-bn-solar-power-projects-jv-5-key-points/88768/

Thursday, May 14, 2015

WINNING TRENDS IN STOCK MARKETS

“PEOPLE ARE NOT DISTURBED BY THINGS RATHER BY THE VIEW OF THINGS” –ALBERT ELLIS, AN AMERICAN PSYCHOLOGIST WHO DEVELOPEDRATIONAL EMOTIVE BEHAVIOUR THERAPY.
THIS PSYCHOLOGICAL APPROACH IS APT TO MANY BUSINESS HOUSE DECISIONS BUT VERY TRUE IN STOCK MARKETS AS VIEWS BECOME PALE & FEARFUL DURING THE TIMES OF DEPRESSIVE NEGATIVE ENVIRONMENTS, JUSTLIKE NIGHTMARES IN  THICK FORESTS OF ABUNDANT DESOLATION.
THE STOCK-MARKETS CLEARLY REPRESENT A FRIGHTENING CLUMSY PICTURE AT TIMES WHEN VOLITITIY AT ITS PEAK & FALL CONTINUES!!, NO MATTER HOW SEASONED SOMEBODY BUT TO OVERCOME THE NERVE WRENCHING FEAR AND FORESEE THE FUTURE BECOMES DREADFUL.
TO AVOID UNCERTAINTIES IN STOCK MARKETS ARE NOT AT ANYBODY'S COMMAND OR CAPACITY BUT EVERY PARTICIPANT'S WISH....
TO MITIGATE THE FEAR AND UNDERSTAND THE EMERGING OPPORTUNITIES IN CHAOS, THE FOLLOWING APPROACHES CAN BE ADOPTED FOR BETTER RESULTS AND TO KEEP PACE WITH THE MARKET TRENDS...!!
A) CONVERGENT PROCESS:
THIS APPROACH IS MORE WIDELY ACCEPTED AND FOLLOWED BY THE FIIs, DIIs AND ESPECIALLY FOR THAT MATTER MORE PRECISELY BY HEDGE FUNDS. THESE HIGH RISK SEASONED CUTTING EDGE SMART PEOPLE PLACE HIGH BETS WITH AN ANTICIPATION OF HIGH RETURNS. THE BLOOM AND GLOOM CO-EXIST MANY A TIMES BUT THEIR SPIRITS ARE VERY HIGH.
HERE, STOCK PURCHASE CONCENTRATION IS SO HIGH THAT HUGE MONEY PUMPED AND LARGE CHUNK ACQUIRED AT A REASONABLE PRICE. THE COMPANY FUNDAMENTALS, ECONOMIC &BUSINESS TRENDS AND OTHER IMPORTANT PARAMETERS ARE LITTLE KNOWN TO OTHER RETAIL PARTICIPANTS BUT GET SURPRISED WHY AND HOW THESE COUNTERS ARE HOLDING ON TO THE TOP. 
LAST BUT NOT LEAST, THE VERY IMPORTANT MARKET MANAGEMENT MECHANISMS ARE PUT IN PLACE TO SEE THE PRICES RISE STEADILY AND GRADUALLY TO A LIMIT AND THEN A FINAL SHOOT UP …?. UNFORTUNATELY THE GREEDY POOR TRADERS AND RETAIL INVESTORS GET TRAPPED WHEN PARTICIPATE HEAVILY AND OFCOURSE THE WELL INFORMED SEEK AN EXIT…???
B) DIVERGENT PROCESS:
MAINLY FOLLOWED BY HNIs AND SMALL FUND HOUSES. THE PHILOSOPHY IS TO PROTECT THE CAPITAL AND INCREASE PROFITS IN BABY STEPS. THESE INVESTORS NEVER KEEP ALL EGGS IN ONE BASKET BUT PREFER DIFFERENT SECTORS. THIS DIVERGENT MEANS OF MAKING MONEY CAN OFFER SOLACE THAN ANY OTHER MODEL AS THE MARKET WAGGERIES ARE WELL TAKEN CARE. 
THESE PLAYERS ARE MODERATE IN RISK TAKING APPROACH, HAVE GOOD CONFIDENCE IN MARKETS BUT FEARFUL IN APPROACH. THEY ADOPT LONG-TERM PLAY WITH AN EYE ON SHORT-TERM GAINS, PLACE THEM IN GOOD POSITION AS THEY OFTEN TAKE-OUT PROFITS AT HIGHER LEVELS AND RE-ENTER AT LOWER LEVELS. SO, SAFE AND SECURE ALL THE TIME.
C) CHANNELLED PROCESS:
THE LADDER LIKE APPROACH IS ADOPTED BY SMART INDIVIDUALS TO ENSURE SUCCESS AT EVERY MOVE  WITH A LIMITED RESOURCE/MONEY. THEY KEEP MAINTAIN A WINNING STEAK ON BOTH THE DIRECTIONAL MOVES, SAIL ALONG WITH BULLS AND BEARS AS THEIR ADAPTABILITY & LIQUIDITY AT HAND ALLOWS SUCH FACILITY. THEY KEEP INCREASE VERY CALCULATED BETS, ALSO MAKE SUCCESS, A COMMON PHENOMENA LIKE CLIMBING A LADDER.
THESE PLAYERS ARE KNOWLEDGEABLE AND QUITE SMART IN CATCHING TRENDS IN THE MARKETS AND PLACE THEIR BETS SAFELY, ALSO MAKE SOME GOOD MONEY. THE PLAYERS SUCK EACH EMERGING OPPORTUNITIES IN STOCK MOVEMENTS BUT THEIR WELL ESTABLISHED APPROACH IS NOT KNOWN IN THE MARKET CIRCLES BUT MAKE DECENT COOL MONEY.
D) ZIG-ZAG JUMPING PROCESS: 
THIS APPROACH IS MOSTLY ADOPTED BY THE DAY TRADERS AND SWING TRADERS, ENJOY BUYING AND SELLING MANY A TIMES DURING THE DAY.THESE ENTHUSIASTIC TRADING PLAYERS ARE BACK-BONE TO MARKET LIQUIDITY AND FOR STOCK-TIPS ADVISORS. THEY KEEP ENGAGED EVERY TIME AND EACH TIME THEY TAKE A CALL AS THEIR GAME IS HIGHLY VOLATILE AND NO-BODY UNDERSTANDS WHY A BUYING IS MADE AND INSTANTLY A SELLING IS INITIATED. MANY A TIMES THEY BUY AT ONE COUNTER AND ALSO SELL ANOTHER SCRIP. ULTIMATELY, THEY ENJOY PARTICIPATION RATHER THAN MAKING MONEY.
THESE SMALL TIME RATHER INSTANT PLAYERS NEVER MAKE HUGE MONEY STORED IN THE MARKETS BUT LOSE MONEY FOR SURE, BECAUSE OF BUNDLE OF CONFUSIONS!. THE MORE THEY PLAY THE MORE THEY PAY. THEY HARDLY MAINTAIN ANY ORDER/METHOD, FIND NO TIME TO STUDY, PREFER EXTERNAL DEPENDENCY, MAINTAIN ADAMANT BEHAVIOUR TO A LOSING DEALS, RELY ON IRRATIONAL MEDIA COVERAGES & LIVE IN RUMORS AND PLACE HUGE BETS, BELIEVE IN CARRY ALONG WITH THE MOB IN THE MARKETS...ETC. ALL THE MORE, TAKE VERY FRAGILE DECISIONS AND UN-MINDFULLY INVITE HIGH-RISKS, UNFORTUNATELY GO INTO DUST...UN-NOTICED!!!!

Tuesday, May 12, 2015

SENSEX-MOVEMENT


YearOpenHighLowClose
19911027.381955.29947.141908.85
19921965.684546.581945.482615.37
19932617.783459.071980.063346.06
19943436.874643.313405.883926.9
19953910.163943.662891.453110.49
19963114.084131.222713.123085.2
19973096.654605.413096.653658.98
19983658.3443222741.223055.41
19993064.955150.993042.255005.82
20005209.546150.693491.553972.12
20013990.654462.112594.873262.33
20023262.013758.272828.483377.28
20033383.855920.762904.445838.96
20045872.486617.154227.56602.69
20056626.499442.986069.339397.93
20069422.4914035.38799.0113786.91
200713827.7720498.1112316.120286.99
200820325.2721206.777697.399647.31
20099720.5517530.948047.1717464.81
201017473.4521108.6415651.9920509.09
201120621.6120664.815135.8615454.92
201215534.6719612.1815358.0219426.71
201319513.4521483.7417448.7121170.68
201421222.1928822.3719963.1227499.42
201527485.7730024.7426776.1227011.31

Sunday, December 28, 2014

Rs 3 lakh crore investment--POWER!!!

Govt eyes Rs 3 lakh crore investment, reforms to light up power sector

Piyush Goyal has already laid out an ambitious target of the new govt to provide 24X7 power supply to all households in the country by March 2019

Friday, December 26, 2014

BIOSIMILARS...BIG OPPORTUNITY FOR PHARMA...!!!!

Biosimilars are the next big thing for Indian pharma
By:  | Mumbai | December 27, 2014 1:31 amWhile the US is still ironing out its rules governing generic equivalents of biologic drugs, also known as biosimilars, the Indian market has witnessed nearly 20% annual growth for the year ending November 2014 in the segment.Biologics are drugs whose active ingredients are sourced from living organisms so these products are based on proteins, genes, etc, unlike normal small-molecule drugs where the active ingredient is a chemical.Due to this complex base, biologics are not as easily copied as other drugs and companies that are leading such research in India are the top pharmaceutical firms such as Biocon, Dr Reddy’s,  Lupin and Cadila Healthcare.A recent HSBC report says that biosimilar sales grew 20% annually to Rs 2,000 crore or approximately 2.5% of overall market sales at the end of November 2014. Sales margins on biosimilar drugs range from 20% to 80%, according to analysts. On the other hand, almost 90% to 95% of the innovator price of a drug is eroded when a generic version of a small-molecule drug is launched.With the US drug patent pipeline drying up, it is the high-margin biologics that will sustain sales for Indian companies,  analysts.On December 9, the BSE-listed Cadila announced the launch of a copycat version of AbbVie’s blockbuster biologic, Humira, which targets autoimmune disorders such as rheumatoid arthritis. The drug is touted as world’s top-selling drug with global sales exceeding Rs 1,000 crore in CY13, according to the HSBC report. The biosimilar, named Exemptia, will be marketed as a 40 mg injection administered once every alternate week and launched at one-fifth of Humira’s price of approximately $1,000 per injection.graph3Similarly, in April 2013, Cipla started selling a biosimilar of the rheumatoid arthritis drug Enbrel with a launch price of $100. The price of the drug from the innovator, Amgen, was $133.Biocon’s CANMab, a breast cancer therapy that is a generic of Roche’s Herceptin, was launched in February 2014 with a 25% discount to the innovator price.“While we are excited with novel launches even in emerging markets given better pricing, we believe a significant contribution is far away as the market is still at nascent stage in accepting newer better forms of treatments coming at higher costs,” HSBC analysts wrote.Dr Reddy’s, especially, has the most exposure to biosimilars with approximately 7% or Rs 110 crore of its FY14 India sales originating from biosimilars compared with 3.7% for Cadila and less than 1% for Lupin and Cipla, according to HSBC analysts. “Dr Reddy’s is upping the ante on investing in complex generics as well as more risky areas involving biosimilars and proprietary products,” IDFC analysts wrote in a note dated October 29. “While limited visibility on value unlocking from the aggressive R&D investments in these spaces is a challenge, we see significant value creation possibilities given Dr Reddy’s proven capabilities in these high potential areas.”The European Medicines Agency has approved seven types of biosimilars from 2009 till date, according to data available on its website. None of the companies listed are Indian. In 2014, it approved the a single biosimilar: Sanofi’s insulin glargine therapy for diabetics named Lantus. The US Food and Drug Administration is yet to approve any biosimilar. “Material entry in regulated markets (US, EU) is still 4-5 years away as per our understanding,” HSBC analysts wrote.http://www.financialexpress.com/article/economy/biosimilars-are-the-next-big-thing-for-indian-pharma/23516/

Wednesday, December 24, 2014

MERRY CHRISTMAS..&..THERMAX

MIND BOGGLING YET…

I WAS AMAZED TO SEE THE PRICE ROCKETED TO CREATE ENOUGH TURBULENCE IN ME.

I BOUGHT 1000 SHARES OF THERMAX FOR Rs 38.65, 15 YEARS BACK,

TODAY, THE PRICE OF THERMAX IS Rs 1050/- OF Rs 2/- FACE VALUE (EQUAL TO Rs 5150/-). IN OTHER WORDS, ONE LAKH INVESTED HAS BECOME MORE THAN 66 LAKHS.

EVEN RECENTLY, 2-3 YEARS BACK, I FOUND MARKSAN AT Rs 2.30 NOW IT IS QUOTING Rs 64/-.

ALSO FOUND MORARJEE TEXTILES AT Rs 7.0 NOW TOUCHED A HIGH OF Rs 61, INDOCOUNT INDUSTRIES AT Rs 7.0 NOW TOUCHED A HIGH OF Rs 390/-.

BUT THE ABOVE THREE WERE JUST MEMORIES BUT NO PARTICIPATION……


===============================================

MERRY CHRISTMAS TO YOU & ALL INVESTORS & TRADERS…